Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma

Hamayun Imran, Felicity Enders, MarkKrailo, Franklin Sim, Scott Okuno, Douglas Hawkins, Joseph Neglia, R Randall, Richard Womer, Leo Mascarenhas, Carola A.S. Arndt

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: The dose intensity of chemotherapy has been described as affecting the outcome of the treatment of a number of different types of tumors. A delay in the resumption of chemotherapy after definitive surgery for the treatment of osteosarcoma can decrease the overall dose intensity. The goal of this study was to assess the prognostic significance of the time to resumption of chemotherapy after definitive surgery in patients with localized osteosarcoma in an extremity. Methods: The relationships of the time between definitive surgery and resumption of chemotherapy with death and adverse events in 703 patients with a localized resectable osteosarcoma in an extremity (556 treated in the Children's Oncology Group [COG] Study [INT 0133] and 147 treated at five tertiary care cancer centers) were assessed with use of Cox proportional hazards models. Results: The twenty-fifth, fiftieth, and seventy-fifth percentiles of time from definitive surgery to resumption of chemotherapy were twelve, sixteen, and twenty-one days, respectively. Overall survival was poorerfor patients who had had a delay of greater than twenty-one days before the resumption of chemotherapy compared with those who had had a shorterdelay (hazard ratio = 1.57 [95% confidence interval = 1.04 to 2.36]; p = 0.03). Of seventy-one COG-study patients with postoperative complications, 32% (twenty-three) had a delay of more than twenty-one days before resumption of chemotherapy, but 20% (eighty- nine) of 444 patients with no complications had a similar delay. Conclusions: In this retrospective analysis, increased time from the definitive surgery to the resumption of chemotherapy was found to be associated with an increased risk of death of patients with localized osteosarcoma in an extremity. Within the limitations of a retrospective study, the data indicate that it is best to resume chemotherapy within twenty-one days after definitive surgery. Surgeons, oncologists, patients, and those responsible for scheduling need to work together to ensure timely resumption of chemotherapy after surgery. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.

Original languageEnglish (US)
Pages (from-to)604-612
Number of pages9
JournalJournal of Bone and Joint Surgery - Series A
Volume91
Issue number3
DOIs
StatePublished - Mar 1 2009
Externally publishedYes

Fingerprint

Osteosarcoma
Drug Therapy
Extremities
Proportional Hazards Models
Tertiary Care Centers
Neoplasms
Retrospective Studies
Confidence Intervals
Survival

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. / Imran, Hamayun; Enders, Felicity; MarkKrailo; Sim, Franklin; Okuno, Scott; Hawkins, Douglas; Neglia, Joseph; Randall, R; Womer, Richard; Mascarenhas, Leo; Arndt, Carola A.S.

In: Journal of Bone and Joint Surgery - Series A, Vol. 91, No. 3, 01.03.2009, p. 604-612.

Research output: Contribution to journalArticle

Imran, H, Enders, F, MarkKrailo, Sim, F, Okuno, S, Hawkins, D, Neglia, J, Randall, R, Womer, R, Mascarenhas, L & Arndt, CAS 2009, 'Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma', Journal of Bone and Joint Surgery - Series A, vol. 91, no. 3, pp. 604-612. https://doi.org/10.2106/JBJS.H.00449
Imran, Hamayun ; Enders, Felicity ; MarkKrailo ; Sim, Franklin ; Okuno, Scott ; Hawkins, Douglas ; Neglia, Joseph ; Randall, R ; Womer, Richard ; Mascarenhas, Leo ; Arndt, Carola A.S. / Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. In: Journal of Bone and Joint Surgery - Series A. 2009 ; Vol. 91, No. 3. pp. 604-612.
@article{48e046b7bf0e48f4ae865b2b36259b6a,
title = "Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma",
abstract = "Background: The dose intensity of chemotherapy has been described as affecting the outcome of the treatment of a number of different types of tumors. A delay in the resumption of chemotherapy after definitive surgery for the treatment of osteosarcoma can decrease the overall dose intensity. The goal of this study was to assess the prognostic significance of the time to resumption of chemotherapy after definitive surgery in patients with localized osteosarcoma in an extremity. Methods: The relationships of the time between definitive surgery and resumption of chemotherapy with death and adverse events in 703 patients with a localized resectable osteosarcoma in an extremity (556 treated in the Children's Oncology Group [COG] Study [INT 0133] and 147 treated at five tertiary care cancer centers) were assessed with use of Cox proportional hazards models. Results: The twenty-fifth, fiftieth, and seventy-fifth percentiles of time from definitive surgery to resumption of chemotherapy were twelve, sixteen, and twenty-one days, respectively. Overall survival was poorerfor patients who had had a delay of greater than twenty-one days before the resumption of chemotherapy compared with those who had had a shorterdelay (hazard ratio = 1.57 [95{\%} confidence interval = 1.04 to 2.36]; p = 0.03). Of seventy-one COG-study patients with postoperative complications, 32{\%} (twenty-three) had a delay of more than twenty-one days before resumption of chemotherapy, but 20{\%} (eighty- nine) of 444 patients with no complications had a similar delay. Conclusions: In this retrospective analysis, increased time from the definitive surgery to the resumption of chemotherapy was found to be associated with an increased risk of death of patients with localized osteosarcoma in an extremity. Within the limitations of a retrospective study, the data indicate that it is best to resume chemotherapy within twenty-one days after definitive surgery. Surgeons, oncologists, patients, and those responsible for scheduling need to work together to ensure timely resumption of chemotherapy after surgery. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.",
author = "Hamayun Imran and Felicity Enders and MarkKrailo and Franklin Sim and Scott Okuno and Douglas Hawkins and Joseph Neglia and R Randall and Richard Womer and Leo Mascarenhas and Arndt, {Carola A.S.}",
year = "2009",
month = "3",
day = "1",
doi = "10.2106/JBJS.H.00449",
language = "English (US)",
volume = "91",
pages = "604--612",
journal = "Journal of Bone and Joint Surgery - American Volume",
issn = "0021-9355",
publisher = "Journal of Bone and Joint Surgery Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma

AU - Imran, Hamayun

AU - Enders, Felicity

AU - MarkKrailo,

AU - Sim, Franklin

AU - Okuno, Scott

AU - Hawkins, Douglas

AU - Neglia, Joseph

AU - Randall, R

AU - Womer, Richard

AU - Mascarenhas, Leo

AU - Arndt, Carola A.S.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background: The dose intensity of chemotherapy has been described as affecting the outcome of the treatment of a number of different types of tumors. A delay in the resumption of chemotherapy after definitive surgery for the treatment of osteosarcoma can decrease the overall dose intensity. The goal of this study was to assess the prognostic significance of the time to resumption of chemotherapy after definitive surgery in patients with localized osteosarcoma in an extremity. Methods: The relationships of the time between definitive surgery and resumption of chemotherapy with death and adverse events in 703 patients with a localized resectable osteosarcoma in an extremity (556 treated in the Children's Oncology Group [COG] Study [INT 0133] and 147 treated at five tertiary care cancer centers) were assessed with use of Cox proportional hazards models. Results: The twenty-fifth, fiftieth, and seventy-fifth percentiles of time from definitive surgery to resumption of chemotherapy were twelve, sixteen, and twenty-one days, respectively. Overall survival was poorerfor patients who had had a delay of greater than twenty-one days before the resumption of chemotherapy compared with those who had had a shorterdelay (hazard ratio = 1.57 [95% confidence interval = 1.04 to 2.36]; p = 0.03). Of seventy-one COG-study patients with postoperative complications, 32% (twenty-three) had a delay of more than twenty-one days before resumption of chemotherapy, but 20% (eighty- nine) of 444 patients with no complications had a similar delay. Conclusions: In this retrospective analysis, increased time from the definitive surgery to the resumption of chemotherapy was found to be associated with an increased risk of death of patients with localized osteosarcoma in an extremity. Within the limitations of a retrospective study, the data indicate that it is best to resume chemotherapy within twenty-one days after definitive surgery. Surgeons, oncologists, patients, and those responsible for scheduling need to work together to ensure timely resumption of chemotherapy after surgery. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.

AB - Background: The dose intensity of chemotherapy has been described as affecting the outcome of the treatment of a number of different types of tumors. A delay in the resumption of chemotherapy after definitive surgery for the treatment of osteosarcoma can decrease the overall dose intensity. The goal of this study was to assess the prognostic significance of the time to resumption of chemotherapy after definitive surgery in patients with localized osteosarcoma in an extremity. Methods: The relationships of the time between definitive surgery and resumption of chemotherapy with death and adverse events in 703 patients with a localized resectable osteosarcoma in an extremity (556 treated in the Children's Oncology Group [COG] Study [INT 0133] and 147 treated at five tertiary care cancer centers) were assessed with use of Cox proportional hazards models. Results: The twenty-fifth, fiftieth, and seventy-fifth percentiles of time from definitive surgery to resumption of chemotherapy were twelve, sixteen, and twenty-one days, respectively. Overall survival was poorerfor patients who had had a delay of greater than twenty-one days before the resumption of chemotherapy compared with those who had had a shorterdelay (hazard ratio = 1.57 [95% confidence interval = 1.04 to 2.36]; p = 0.03). Of seventy-one COG-study patients with postoperative complications, 32% (twenty-three) had a delay of more than twenty-one days before resumption of chemotherapy, but 20% (eighty- nine) of 444 patients with no complications had a similar delay. Conclusions: In this retrospective analysis, increased time from the definitive surgery to the resumption of chemotherapy was found to be associated with an increased risk of death of patients with localized osteosarcoma in an extremity. Within the limitations of a retrospective study, the data indicate that it is best to resume chemotherapy within twenty-one days after definitive surgery. Surgeons, oncologists, patients, and those responsible for scheduling need to work together to ensure timely resumption of chemotherapy after surgery. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.

UR - http://www.scopus.com/inward/record.url?scp=62549083033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549083033&partnerID=8YFLogxK

U2 - 10.2106/JBJS.H.00449

DO - 10.2106/JBJS.H.00449

M3 - Article

C2 - 19255220

AN - SCOPUS:62549083033

VL - 91

SP - 604

EP - 612

JO - Journal of Bone and Joint Surgery - American Volume

JF - Journal of Bone and Joint Surgery - American Volume

SN - 0021-9355

IS - 3

ER -